As the supporting activity of the second China International Import Expo the RIGVIR® Oncolytic Virotherapy Closed-door Seminar was held in Shanghai on November 7, which is jointly organized by Guizhou Sinorda Biotechnology Company and Latima Company.

This seminar has invited International top Contract Research Organisations (CROs) and senior clinical pharmacology reviewers, as well as oncolytic virothepary scientists and clinicians to attend.

Chinese and foreign experts had a full exchange and discussion on the characteristics and advantages of RIGVIR® oncolytic virotherapy, the regulatory requirements for the application of oncolytic virotherapy drugs (China, Europe and the United States), as well as the selection of indications and the clinical application of RIGVIR® oncolytic virotherapy.

The experts attending this seminar were optimistic about the development of this project and expressed their willingness to cooperate with Guizhou Sinorda to jointly promote the registration, application of RIGVIR® oncolystic virotherapy new drug in China, and also participate in the development of new products.

After the seminar, the R&D team of Sinorda and Latima had an in-depth and constructive communication on the details of the project cooperation.